Elva Zhao: G Protein Regulation and Biased Signaling at the GLP-1 Receptor

The GLP-1 receptor is among the most clinically validated targets in metabolic disease - yet the signaling logic separating the therapeutic benefit of existing drugs from their adverse effects remains poorly resolved. At the center of that problem is biased agonism: the differential engagement of downstream pathways by distinct ligands acting at the same receptor. Understanding which transducer coupling events produce glucose-lowering efficacy and which drive the GI side effects that limit GLP-1 agonist use demands a mechanistic account of receptor-G protein engagement and its regulation.

Elva Zhao brings an unusual vantage point to that question. Her PhD at Western University focused not on receptors but on G protein cycle regulation - RGS proteins, GoLoco proteins, and the kinetics of GTP binding and hydrolysis. That training, initially set aside during postdoctoral work on biased agonism at Monash, is now being reintegrated deliberately. Her current research asks how the regulatory proteins that most GPCR pharmacologists have not yet addressed actually shape signaling output at one of the field's most important therapeutic targets.

The connection runs deeper than science: Zhao's grandmother worked as a pharmacologist on diabetes in China - decades before her granddaughter would begin studying the receptor that now defines modern diabetes pharmacotherapy.

About the Guest

Elva Zhao is a Research Fellow at the Monash Institute of Pharmaceutical Sciences (MIPS), Drug Discovery Biology, in Melbourne, Australia. She completed her PhD at Western University, Canada, under Prof. Peter Chidiac, where her work focused on the kinetic regulation of G protein cycling by RGS proteins and GoLoco motif-containing proteins.

She subsequently joined MIPS for postdoctoral training, working first with Prof. Nigel Bennett on biased signaling at the PAR2 receptor, then with Profs. Denise Wootten and Patrick Sexton on class B GPCR pharmacology and biased agonism at the GLP-1 receptor. Her current research integrates both frameworks - examining how the GLP-1 receptor engages its transducer partners and how G protein regulatory proteins shape downstream signaling in a physiological context.

Scientific Themes of the Conversation

• G protein cycle regulation and the kinetic roles of RGS and GoLoco proteins
  

• Biased agonism at class B GPCRs - ligand-dependent pathway selectivity at the GLP-1 receptor
  

• Transducer coupling as the missing mechanistic layer in GLP-1 receptor pharmacology
  

• The expanding therapeutic profile of the GLP-1 receptor - from diabetes and obesity to neurodegeneration
  

• How collaborative, GPCR-focused research environments change what questions are askable
  

• Scientific identity across discontinuous environments - building a research program across three countries and multiple pharmacological frameworks

Key Insights from the Conversation

1. The G Protein Regulatory Layer GLP-1 Research Has Not Yet Addressed

The pharmacological characterization of GLP-1 receptor agonists has concentrated on receptor-level biased signaling - which downstream pathways are activated - while the proteins that regulate G protein cycle kinetics have received almost no attention in this context. Zhao's research begins to ask what RGS proteins and GoLoco proteins do to modulate the functional output at this receptor, and whether that regulatory layer contributes to the therapeutic window problem that GLP-1 drug development has not solved.

2. Why GLP-1 Drugs Still Produce Nausea - and What Biased Signaling Might Fix

The GI side effects of GLP-1 receptor agonists - primarily nausea and vomiting - remain among the main barriers to broader clinical use and optimal dosing. Zhao describes how the objective of biased agonism research at the GLP-1 receptor is to develop ligand profiles that preserve glucose-lowering efficacy while decoupling the pathways driving adverse effects. Executing that requires knowing, with mechanistic precision, which coupling events map to which clinical outcomes.

3. The Scientific Circle Nobody Plans For

Zhao's PhD - focused entirely on G protein regulation without studying a receptor - appeared to be a separate chapter from her postdoctoral work on receptor pharmacology and biased agonism. A decade later, she is deliberately bringing both ends of that arc together. The insight that G protein regulatory proteins may shape the functional selectivity of GLP-1 agonists in a physiological context is not a planned convergence - it is the result of building two skill sets sequentially and eventually recognizing that neither was complete without the other.

4. GLP-1 Receptor as a Window Into Neurodegeneration

Beyond its established roles in glucose homeostasis and body weight regulation, emerging evidence points to a role for GLP-1 receptor signaling in Parkinson's disease and Alzheimer's disease. Zhao describes how this expanding target profile changes the stakes of understanding how the receptor works - not only in pancreatic beta cells and the periphery, but in neural tissue, where the downstream consequences of biased coupling may differ substantially.

5. What a GPCR-Only Environment Makes Possible

The move from a broad pharmacology department in Canada to the GPCR-focused, shared-space environment at MIPS was scientifically consequential for Zhao. Working alongside structural biologists, computational pharmacologists, and receptor scientists working across GPCR classes gave her the methodological range to ask questions she could not have formulated in a more siloed setting - and access to expertise she could find simply by walking to the right floor with a laptop.

6. Following the Question, Not the Credential

Zhao describes her decision to pursue a postdoc as emerging from a straightforward observation: there was still a question she wanted to answer. Her mentor, Peter Chidiac, had consistently avoided steering her toward a predetermined career path, asking instead which question she most wanted to work on. That framing - orienting around the scientific problem rather than the next credential - organized each subsequent move she made, from Western to Monash, and from G proteins to receptors and back again.

7. The International Student Trap - Nodding Yes When You Don't Understand

One of the frankest passages in the conversation concerns the habit of nodding along when a supervisor is speaking and nothing has been understood - a pattern Zhao describes as nearly universal among international PhD students. The forces behind it are layered: language barriers, cultural conditioning around deference, the general insecurity of early-stage training, and the fear of appearing incompetent. The correction, for Zhao, came slowly - driven by a mentor patient enough to make asking safe, and by the unavoidable evidence that unacknowledged confusion produces problems on both sides of the relationship.

Episode Timeline

Timestamps are AI-generated from the transcript and are approximate. Minor offsets may occur.

• 00:00 Introduction and Dr. GPCR Virtual Cafe announcement

• 01:49 Zhao's scientific background - from Shanghai to Western University

• 06:49 First contact with G proteins - the muscarinic receptor as a tool, not a subject

• 09:17 From China to Canada - the international student experience and the language gap

• 15:09 The mentor who made it safe to say "I don't understand"

• 19:38 Why Australia - how a single conference in Melbourne redirected the next chapter

• 22:28 The decision to pursue a postdoc - following the question before you hate the science

• 28:46 Life at MIPS - collaborative, GPCR-focused, and unexpectedly open

• 32:30 From PAR2 to GLP-1 - building the mechanistic picture one step at a time

• 37:01 GLP-1 receptor biology - diabetes, obesity, and the emerging neurodegenerative angle

• 38:50 Why GLP-1 drugs still need improvement - the side effect problem

• 41:39 Work-life balance - running, Tilly, and what burnout taught about efficiency

• 52:58 COVID as unexpected space to think, organize data, and build collaborations

• 57:58 Advice for trainees - staying curious, knowing your question, and talking to people

Selected Quotes

About this episode

Elva is currently a research fellow at the Monash Institute of Pharmaceutical Sciences. Elva moved to Canada where she obtained her Ph.D. at the University of Western Ontario, working on the regulation of G proteins signaling by accessory proteins, such as RGS proteins and GPSM proteins.

After her Ph.D., she moved to Australia and continues working on GPCRs. Her current research focuses on class B GPCRs and understanding how GPCR signaling and function is mediated by various ligands, binding partners, and intracellular machinery. In her spare time, Elva likes to run in the mountains, play with Tilly (a 9-year old retired greyhound), collecting mini shoes, and hang out with friends.

Join me to learn more about Elva, class B GPCRs, and Tilly.

Dr. Elva Zhao on the web

• LinkedIn

• Monash University

• Pubmed

• Twitter

• Dr. GPCR Ecosystem